121 related articles for article (PubMed ID: 23221606)
41. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J
Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154
[TBL] [Abstract][Full Text] [Related]
42. Uterine epithelioid endometrial stromal sarcoma presenting as a "cervical polyp".
Goh SG; Chuah KL; Chew SH; Tan PH
Ann Diagn Pathol; 2005 Apr; 9(2):101-5. PubMed ID: 15806518
[TBL] [Abstract][Full Text] [Related]
43. Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma.
Arita S; Kikkawa F; Kajiyama H; Shibata K; Kawai M; Mizuno K; Nagasaka T; Ino K; Nomura S
Int J Gynecol Cancer; 2005; 15(2):329-36. PubMed ID: 15823121
[TBL] [Abstract][Full Text] [Related]
44. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
45. PDGF-alpha and PDGF-beta are expressed in endometrial stromal sarcoma: a potential therapeutic target for tyrosine kinase inhibitors?
Liegl B; Reich O; Nogales FF; Regauer S
Histopathology; 2006 Nov; 49(5):545-6. PubMed ID: 17064305
[No Abstract] [Full Text] [Related]
46. Endometrial stromal sarcoma: clinicopathological and immunophenotypic study of 16 cases.
Iwasaki S; Sudo T; Miwa M; Ukita M; Morimoto A; Tamada M; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Sakuma Y; Mikami Y; Nishimura R
Arch Gynecol Obstet; 2013 Aug; 288(2):385-91. PubMed ID: 23435725
[TBL] [Abstract][Full Text] [Related]
47. Endometrial stromal sarcoma arising from endometriosis: a clinicopathological study and literature review.
Lan C; Huang X; Lin S; Cai M; Liu J
Gynecol Obstet Invest; 2012; 74(4):288-97. PubMed ID: 22986788
[TBL] [Abstract][Full Text] [Related]
48. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
Ma BB; Poon TC; To KF; Zee B; Mo FK; Chan CM; Ho S; Teo PM; Johnson PJ; Chan AT
Head Neck; 2003 Oct; 25(10):864-72. PubMed ID: 12966511
[TBL] [Abstract][Full Text] [Related]
49. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
50. Evolution in endometrial cancer: evidence from an immunohistochemical study.
Vandenput I; Trovik J; Leunen K; Wik E; Stefansson I; Akslen L; Moerman P; Vergote I; Salvesen H; Amant F
Int J Gynecol Cancer; 2011 Feb; 21(2):316-22. PubMed ID: 21734474
[TBL] [Abstract][Full Text] [Related]
51. SLUG expression is an indicator of tumour recurrence in high-grade endometrial carcinomas.
Kihara A; Wakana K; Kubota T; Kitagawa M
Histopathology; 2016 Sep; 69(3):374-82. PubMed ID: 27003026
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathologic parameters and immunohistochemical study of endometrial stromal sarcomas.
Wu TI; Chou HH; Yeh CJ; Hsueh S; Yang JE; Jao MS; Chang TC; Hsu CS; Lin KH; Lai CH
Int J Gynecol Pathol; 2013 Sep; 32(5):482-92. PubMed ID: 23896713
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of Wnt7a is associated with tumor progression and unfavorable prognosis in endometrial cancer.
Liu Y; Meng F; Xu Y; Yang S; Xiao M; Chen X; Lou G
Int J Gynecol Cancer; 2013 Feb; 23(2):304-11. PubMed ID: 23321718
[TBL] [Abstract][Full Text] [Related]
54. Immunoexpression of PAX 8 in endometrial cancer: relation to high-grade carcinoma and p53.
Brunner AH; Riss P; Heinze G; Meltzow E; Brustmann H
Int J Gynecol Pathol; 2011 Nov; 30(6):569-75. PubMed ID: 21979593
[TBL] [Abstract][Full Text] [Related]
55. Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer.
Polychronidou G; Kotoula V; Manousou K; Kostopoulos I; Karayannopoulou G; Vrettou E; Bobos M; Raptou G; Efstratiou I; Dionysopoulos D; Chatzopoulos K; Lakis S; Chrisafi S; Tsolakidis D; Papanikolaou A; Dombros N; Fountzilas G
PLoS One; 2018; 13(12):e0208221. PubMed ID: 30521558
[TBL] [Abstract][Full Text] [Related]
56. Expression of androgen receptors in benign and malignant endometrial stromal neoplasms.
Moinfar F; Regitnig P; Tabrizi AD; Denk H; Tavassoli FA
Virchows Arch; 2004 May; 444(5):410-4. PubMed ID: 15007645
[TBL] [Abstract][Full Text] [Related]
57. Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients.
Khabaz MN; Abdelrahman AS; Butt NS; Al-Maghrabi B; Al-Maghrabi J
Ann Diagn Pathol; 2017 Oct; 30():47-51. PubMed ID: 28965628
[TBL] [Abstract][Full Text] [Related]
58. CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer.
Liu P; Sun YL; Du J; Hou XS; Meng H
Int J Gynecol Cancer; 2012 May; 22(4):586-92. PubMed ID: 22266931
[TBL] [Abstract][Full Text] [Related]
59. Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases.
Bai H; Yang J; Cao D; Huang H; Xiang Y; Wu M; Cui Q; Chen J; Lang J; Shen K
Gynecol Oncol; 2014 Mar; 132(3):654-60. PubMed ID: 24412112
[TBL] [Abstract][Full Text] [Related]
60. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
